SHARE @ Advocate Health - Midwest
Not a member yet
11210 research outputs found
Sort by
Inside Aurora Sinai Medical Center, 2002 June
No full textAurora Sinai Medical Center, Milwaukee, WI: Internal employee newsletter with workplace anniversaries, news, and events.https://institutionalrepository.aah.org/alldocuments/2242/thumbnail.jp
Inside Aurora Sinai Medical Center, 2003 February
No full textAurora Sinai Medical Center, Milwaukee, WI: Internal employee newsletter with workplace anniversaries, news, and events.https://institutionalrepository.aah.org/alldocuments/2248/thumbnail.jp
Connection, 1996 October 23
No full textSinai Samaritan Medical Center, Milwaukee, WI: Internal publication for staff and volunteers. This issue highlights the hospital\u27s inclusion on the U.S. News & World Report list of America\u27s Best Hospitals.https://institutionalrepository.aah.org/alldocuments/2236/thumbnail.jp
Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102)
No full textBackground: Reference sets are needed to evaluate performance of multi-cancer detection (MCD) assays. The National Cancer Institute (NCI) funded the Alliance reference set study to assess MCDs for use in future trials.
Methods: Individuals with cancer and controls were recruited; blood specimens were collected prior to cancer treatment. A performance evaluation study was designed utilizing reference set samples. Companies (n = 6) were selected to participate based on review of performance data and ability to utilize the blood collection tube. Companies received samples from cancer types their assay was designed to detect ( targeted ), plus additional non-targeted and control samples. Companies reported positive/negative calls, risk scores, and tissue-of-origin (TOO) predictions. Sensitivity was computed for early (I-II) and late (III-IV) stage cases, based on positive/negative calls (SEPN) and at fixed 98% specificity (SE98). Specificity and TOO accuracy were computed.
Results: 549 cases (encompassing 13 cancer types) and 413 controls from the reference set were included in the study. Companies assessed samples from median 6 (range 5-9) targeted cancer types and median 8 (range: 7-11) overall cancer types. Median (range) specificity was 92.3% (76.5%-98.5%). Median (range) SEPN was 32% (25%-42%) for early stage 73% (48%-89%) for late stage; while median (range) SE98 was 19% (8%-35%) for early stage and 66% (13%-79%) for late stage. Median sensitivity for non-targeted types was 40% (early stage) and 52% (late stage). Median (range) TOO accuracy (primary predicted site) was 75% (64%-78%).
Conclusions: Sensitivity and specificity varied widely across assays with early-stage sensitivity substantially lower than late-stage sensitivity
Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE-assessed meta-analysis of randomized trials with trial sequential evidence
No full textAims: Obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor, has demonstrated potent LDL-C lowering in recent phase 2/3 trials. We evaluated Obicetrapib (1, 2.5, 5, and 10 mg) efficacy and safety in adults with dyslipidemia, with or without atherosclerotic cardiovascular disease (ASCVD) risk.
Materials and methods: We performed a meta-analysis of randomized controlled trials (RCTs) identified through PubMed, Cochrane, Scopus, and Web of Science up to June 2025. Dichotomous outcomes were analyzed as risk ratios (RRs) and continuous outcomes as mean differences (MDs), both with 95% confidence intervals (CIs).
Prospero id: CRD420251107076.
Results: Six RCTs including 3399 patients were analysed. Compared with placebo, Obicetrapib significantly reduced LDL-C at 8-12 weeks (MD -27.66 mg/dL (-26.96%); 95% CI -33.62 to -21.70; p \u3c 0.0001) and non-HDL-C (MD -35.41 mg/dL (-28.08%); 95% CI -39.42 to -31.39; p \u3c 0.0001). It also increased HDL-C (MD 70.85 mg/dL (141.7%); 95% CI 62.56-79.15; p \u3c 0.0001) and improved achievement of LDL-C targets:
Conclusion: Obicetrapib provides substantial improvements in lipid parameters with a favourable short-term adverse events rate. These results support its role as a potential adjunctive lipid-lowering agent irrespective of ASCVD risk. Longer-term trials are warranted to confirm its durability, cardiovascular outcomes, and safety
Comparative effectiveness and safety of PI-Rd triplets in relapsed/refractory multiple myeloma: INSIGHT-MM data analysis
No full textObjectives: To assess the effectiveness/safety of three proteasome inhibitors (PIs), plus lenalidomide-dexamethasone (Rd) triplet regimens, for the treatment of relapsed/refractory multiple myeloma (RRMM) in a real-world setting, using data from the observational INSIGHT-MM study (NCT02761187).
Methods: Adults with RRMM who received ixazomib, carfilzomib, or bortezomib plus Rd (IRd, KRd, or VRd, respectively) in the second or later line of therapy (LoT) were included. Patient characteristics, response to therapy (Kaplan-Meier analysis), and safety were reported descriptively. Multivariable Cox proportional hazards models were used to assess comparative effectiveness between regimens, whilst adjusting for cohort imbalances.
Results: Overall, 356 LoTs (IRd n = 181; KRd n = 96; VRd n = 79) from 348 patients were included. There was heterogeneity in patient characteristics between cohorts. Median real-world progression-free survival (rwPFS) for IRd, KRd, and VRd was 14.5, 13.2, and 9.1 months, respectively. After adjustment for baseline covariates, no significant differences in rwPFS were observed between regimens. All three regimens demonstrated a manageable safety profile.
Conclusions: IRd, KRd, and VRd demonstrated comparable effectiveness and safety for the treatment of RRMM in a real-world setting, highlighting the need for a holistic evaluation of individual patients\u27 needs and circumstances when selecting an appropriate PI
Tirzepatide and cardiovascular outcomes: A narrative review of mechanisms, efficacy and implications for heart failure management
No full textBackground: Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers a novel cardiometabolic strategy beyond glycemic control with important implications for heart failure care. By producing potent, sustained weight reduction and favourable changes in lipids, blood pressure, systemic inflammation and endothelial biology, tirzepatide targets central pathophysiologic drivers of obesity-related HFpEF.
Methods: We conducted this review to synthesise current evidence on the mechanisms, clinical efficacy and therapeutic implications of tirzepatide for heart failure management, with emphasis on obesity-related HFpEF, cardiorenal effects and safety considerations. Randomised clinical programmes and the SUMMIT outcomes trial have demonstrated symptomatic and functional improvements, reverse cardiac remodelling on imaging, reduced circulating markers of myocardial stress and fewer worsening heart-failure events versus placebo, alongside signals of renal stabilisation.
Results: The tolerability profile aligns with the GLP-1 class, with gastrointestinal events predominating and a low risk of clinically important hypoglycemia; biliary events may be more likely at higher doses, while pancreatitis risk has not been clearly elevated. Data in HFrEF remain limited and caution is advised given prior mixed results with incretin therapies and theoretical concerns about rapid weight loss in advanced systolic failure.
Conclusion: This review integrates mechanistic insights and contemporary trial evidence to clarify how dual incretin agonism may modify the trajectory of obesity-driven heart failure, to inform multidisciplinary clinical decision making, and to highlight key unanswered questions and research priorities needed to define tirzepatide\u27s full role in heart failure management
PTSD symptoms and substance use problems in traumatic injury patients: A 24-month follow-up
No full textBACKGROUND: People who experience traumatic injuries may be at risk for a variety of post-injury emotional and behavioral sequalae. In particular, the level of trauma experienced in relation to those injuries may place individuals at increased risk for substance use-related problems. Given the lack of research directly investigating the impact of injury-related PTSD on substance use problems post-injury, we conducted a secondary analysis of a study of injured patients to explore this issue.
METHODS: To address the hypothesis that those experiencing more trauma at baseline were at increased risk for substance use problems at follow-up, this study utilized a prospective longitudinal design to investigate the relationship between traumatic injury, PTSD symptoms, and drug use problems over a 24-month follow-up period in 215 patients with traumatic injuries admitted for treatment to an urban Level 1 trauma center. The main study aim was to investigate whether the baseline major of trauma was associated with higher levels of substance use problems at follow-up, controlling for key background variables. Accordingly, we conducted mixed model longitudinal regression analysis where the 10-item DAST was regressed on time, demographic variables (age, sex, race, and income), and initial post-injury PTSD symptoms (as measured by the PCL-5 assessed two weeks post-injury). Separate analyses were conducted using continuous and binary measures of the DAST-10.
RESULTS: Forty-two percent of the sample exceeded the clinical threshold for PTSD. Elevated PTSD symptoms increased the risk for the emergence of substance use problems over the follow-up period. The impact of PTSD symptoms remained when we looked at continuous and binary indicators of substance use problems, and when we controlled for retrospectively reported substance use problems. Male sex, older age, and lower income were also associated with the emergence of substance use problems.
CONCLUSION: PTSD symptoms occurring immediately post-injury, when elevated, lead to an increased risk for the emergence of substance use problems at follow-up. Substance use problems at follow-up are not merely a continuation of problems experienced before the injury. These findings underscore the importance of screening and of psychologically focused interventions soon after the traumatic injury experience